
Opinion|Videos|June 11, 2024
Alternative Treatments for eBC and mBC
Key opinion leaders (KOLs) discuss the use of CDK4/6 inhibitors in early breast cancer, specifically in patients who have undergone chemotherapy and surgery. They highlight the key factors that help determine which patients are most likely to benefit from receiving these medications.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Which phase of treatment is abemaciclib appropriate in?
- What are the patient characteristics that must be present in order to utilize abemaciclib?
- Do these criteria influence your treatment decisions in patients with early breast cancer?
- What is the study design and methods of the NATALEE trial and what have the results demonstrated so far?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Gluteus Maximus Muscle Shape Changes Tied to Aging, Frailty, and Type 2 Diabetes
2
FDA Approves Reformulated Ranitidine After 5-Year Absence
3
Redefining the Role of GLP-1 Therapies: The Clinical Trials Behind the Expanding Indications
4
Updated Hypertension Guidelines Are Here
5




















































































































































































































